专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060247240A1 Method of treatment and/or prevention of brain, spinal or nerve injury 审中-公开
标题翻译：治疗和/或预防脑，脊髓或神经损伤的方法
公开(公告)号：US20060247240A1
公开(公告)日：2006-11-02
申请号：US11481216
申请日：2006-07-05
申请人： Torsten Hoffmann , Alan Nimmo , Andrew Sleight , Pierre Vankan , Robert Vink
发明人： Torsten Hoffmann , Alan Nimmo , Andrew Sleight , Pierre Vankan , Robert Vink
IPC分类号： A61K31/5377 , A61K31/496 , A61K31/455
CPC分类号： A61K31/435
摘要： The invention relates to a method of treatment and/or prevention of brain, spinal or nerve injury comprising administration to a person in need of such treatment, of a therapeutically effective amount of an NK-1 receptor antagonist compound of the formula wherein the meanings of R, R1, R2, R2, R3, and R4 are explained in the specification and the pharmaceutically acceptable acid addition salts and the prodrugs thereof either alone or in combination with a magnesium salt. Exemplified is the use of N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide. The invention also relates to pharmaceutical composition comprising one or more such NK-1 receptor antagonists, optionally in combination with a magnesium salt, and a pharmaceutically acceptable excipient for the treatment and/or prevention of brain, spinal or nerve injury.
摘要翻译：本发明涉及一种治疗和/或预防脑，脊髓或神经损伤的方法，包括向需要这种治疗的人施用治疗有效量的下式的NK-1受体拮抗剂化合物，其中， R 1，R 2，R 2，R 2，R 3和R 4， SUP>在本说明书和药学上可接受的酸加成盐及其前药中单独或与镁盐组合进行说明。举例说明了使用N-（3,5-双 - 三氟甲基 - 苄基）-N-甲基-6-（4-甲基 - 哌嗪-1-基）-4-邻甲苯基 - 烟酰胺。本发明还涉及包含一种或多种这样的NK-1受体拮抗剂，任选与镁盐组合的药物组合物和用于治疗和/或预防脑，脊髓或神经损伤的药学上可接受的赋形剂。

2. 发明申请

US20090208425A1 TRANSMUCOSAL ADMINISTRATION OF 2,3-DIMETHOXY-5-METHYL-6-(10-HYDROXYDECYL)-1,4-BENZOQUINONE 审中-公开
标题翻译： 2,3-二甲基-5-甲基-6-（10-羟基丁基）-1,4-苯并噻喃的转移体系
公开(公告)号：US20090208425A1
公开(公告)日：2009-08-20
申请号：US12375586
申请日：2007-08-03
申请人： Judith Dubach-Powell , Rudolf Hausmann , Pierre Vankan
发明人： Judith Dubach-Powell , Rudolf Hausmann , Pierre Vankan
IPC分类号： A61K9/68 , A61K31/122 , A61P25/28
CPC分类号： A61K31/122
摘要： Use of idebenone for the preparation of a medicament for transmucosal administration.
摘要翻译：艾地苯醌用于制备经粘膜给药的药物。

3. 发明申请

US20110053954A1 METHOD OF TREATMENT AND/OR PREVENTION OF BRAIN, SPINAL OR NERVE INJURY 审中-公开
标题翻译：治疗和/或预防脑，脊髓或神经损伤的方法
公开(公告)号：US20110053954A1
公开(公告)日：2011-03-03
申请号：US12886691
申请日：2010-09-21
申请人： Torsten Hoffmann , Alan Nimmo , Andrew Sleight , Pierre Vankan , Robert Vink
发明人： Torsten Hoffmann , Alan Nimmo , Andrew Sleight , Pierre Vankan , Robert Vink
IPC分类号： A61K31/496 , A61P25/00
CPC分类号： A61K31/435
摘要： The invention relates to a method of treatment and/or prevention of brain, spinal or nerve injury comprising administration to a person in need of such treatment, of a therapeutically effective amount of an NK-1 receptor antagonist compound of the formula wherein the meanings of R, R1, R2, R2′, R3, and R4 are explained in the specification and the pharmaceutically acceptable acid addition salts and the prodrugs thereof either alone or in combination with a magnesium salt. Exemplified is the use of N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide. The invention also relates to pharmaceutical composition comprising one or more such NK-1 receptor antagonists, optionally in combination with a magnesium salt, and a pharmaceutically acceptable excipient for the treatment and/or prevention of brain, spinal or nerve injury.
摘要翻译：本发明涉及一种治疗和/或预防脑，脊髓或神经损伤的方法，包括向需要这种治疗的人施用治疗有效量的下式的NK-1受体拮抗剂化合物，其中，说明书和其药学上可接受的酸加成盐及其前药单独或与镁盐组合说明了R，R 1，R 2，R 2'，R 3和R 4。举例说明了使用N-（3,5-双 - 三氟甲基 - 苄基）-N-甲基-6-（4-甲基 - 哌嗪-1-基）-4-邻甲苯基 - 烟酰胺。本发明还涉及包含一种或多种这样的NK-1受体拮抗剂，任选与镁盐组合的药物组合物和用于治疗和/或预防脑，脊髓或神经损伤的药学上可接受的赋形剂。

4. 发明申请

US20060228752A1 Genetic polymorphisms in the preprotachykinin gene 审中-公开
标题翻译：前列腺素基因的遗传多态性
公开(公告)号：US20060228752A1
公开(公告)日：2006-10-12
申请号：US11472083
申请日：2006-06-21
申请人： Dorothee Foernzler , Lara Hashimoto , Jia Li , Eric Luedin , Andrew Sleight , Pierre Vankan
发明人： Dorothee Foernzler , Lara Hashimoto , Jia Li , Eric Luedin , Andrew Sleight , Pierre Vankan
IPC分类号： C12Q1/68 , A61K31/5377 , C07H21/04
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to a method for correlating single nucleotide polymorphisms in the preprotachykinin (NKNA) gene with the efficacy and compatibility of a pharmaceutically active compound administered to a human being. The invention further relates to a method for determining the efficacy and compatibility of a pharmaceutically active compound administered to a human being which method comprises determining at least one single nucleotide polymorphism in the NKNA gene. Said methods are based on determining specific single nucleotide polymorphisms in the NKNA gene and determining the efficacy and compatibility of a pharmaceutically active compound in the human by reference to polymorphism in NKNA. The invention further relates to isolated nucleic acids comprising within their sequence the polymorphisms as defined herein, to nucleic acid primers and oligonucleotide probes capable of hybridizing to such nucleic acids and to a diagnostic kit comprising one or more of such primers and probes for detecting a polymorphism in the NKNA gene, to a pharmaceutical pack comprising NK-1 receptor antagonists and instructions for administration of the drug to human beings tested for the polymorphisms as well as to a computer readable medium with the stored sequence information for the polymorphisms in the NKNA gene.
摘要翻译：本发明涉及一种使前列腺素激素（NKNA）基因中的单核苷酸多态性与施用于人的药学活性化合物的功效和相容性相关联的方法。本发明还涉及确定施用于人的药物活性化合物的功效和相容性的方法，该方法包括测定NKNA基因中的至少一个单核苷酸多态性。所述方法基于确定NKNA基因中的特异性单核苷酸多态性，并参考NKNA中的多态性确定药物活性化合物在人体中的功效和相容性。本发明还涉及在其序列中包含本文所定义的多态性的分离的核酸与能够与此类核酸杂交的核酸引物和寡核苷酸探针以及包含一种或多种用于检测多态性的引物和探针的诊断试剂盒在NKNA基因中，涉及包含NK-1受体拮抗剂的药物组合物，以及向该多态性测试的人给药的说明书以及具有存储的NKNA基因多态性序列信息的计算机可读介质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式